Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3007160#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 3007160.bibtex.
- aggregation hasFormat 3007160.csv.
- aggregation hasFormat 3007160.dc.
- aggregation hasFormat 3007160.didl.
- aggregation hasFormat 3007160.doc.
- aggregation hasFormat 3007160.json.
- aggregation hasFormat 3007160.mets.
- aggregation hasFormat 3007160.mods.
- aggregation hasFormat 3007160.rdf.
- aggregation hasFormat 3007160.ris.
- aggregation hasFormat 3007160.txt.
- aggregation hasFormat 3007160.xls.
- aggregation hasFormat 3007160.yaml.
- aggregation isPartOf urn:issn:0724-8741.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment".
- aggregation abstract "To develop a nanocrystalline paclitaxel formulation with a high paclitaxel-to-stabilizer ratio which can be used for hyperthermic intraperitoneal chemotherapy (HIPEC). Paclitaxel (PTX) nanocrystals were prepared via wet milling using Pluronic F127(A (R)) as stabilizer. The suitability of paclitaxel nanosuspensions for HIPEC treatment was evaluated by analyzing the cytotoxicity of both stabilizer and formulation, and by determining the maximum tolerated dose (MTD) and bioavailability. The effect on tumor growth was evaluated by magnetic resonance imaging (MRI) at day 7 and 14 after HIPEC treatment in rats with peritoneal carcinomatosis of ovarian origin. Monodisperse nanosuspensions (+/- 400 nm) were developed using Pluronic F127(A (R)) as single additive. The cytotoxicity and MTD of this nanocrystalline formulation was similar compared to Taxol(A (R)), while its bioavailability was higher. MRI data after HIPEC treatment with a PTX nanocrystalline suspension showed a significant reduction of tumor volume compared to the non-treated group. Although no significant differences on tumor volume were observed between Taxol(A (R)) and the nanosuspension, the rats treated with the nanosuspension recovered faster following the HIPEC procedure. Nanosuspensions with a high paclitaxel-to-stabilizer ratio are of interest for the treatment of peritoneal carcinomatosis of ovarian origin via HIPEC.".
- aggregation authorList BK675747.
- aggregation endPage "2406".
- aggregation issue "9".
- aggregation startPage "2398".
- aggregation volume "29".
- aggregation aggregates 3007271.
- aggregation aggregates 3007901.
- aggregation isDescribedBy 3007160.
- aggregation similarTo s11095-012-0765-x.
- aggregation similarTo LU-3007160.